Visual Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter-2 inhibitor (SGLT-2i) combination data are limited. The SUSTAIN 10 trial analyzed the efficacy and safety of the GLP-1RAs semaglutide 1.0 mg and liraglutide 1.2 mg in subjects with type 2 diabetes. This post hoc analysis of SUSTAIN 10 examined clinical outcomes with these GLP-1RAs in subjects on background SGLT-2i and in those not receiving an SGLT-2i. In this post hoc analysis, SUSTAIN 10 data were stratified by SGLT-2i use at screening. ‘On-treatment without rescue medication’ and ‘on-treatment’ data were used to assess efficacy (HbA1c, body weight [BW] and systolic blood pressure [SBP]) and safety (discontinuation due to adverse events [AEs]) outcomes, respectively. Within each SGLT-2i subgroup, baseline characteristics and background medications (metformin and/or sulfonylureas) were similar between treatment arms. Reductions from baseline to week 30 in HbA1c, BW and SBP were observed with semaglutide 1.0 mg and liraglutide 1.2 mg regardless of SGLT-2i use (Figure). There were no unexpected safety concerns in subjects receiving GLP-1RA and SGLT-2i, and discontinuations due to AEs remained relatively low in both SGLT-2i subgroups.

In conclusion, the results suggest that addition of a GLP-1RA to SGLT-2i treatment was associated with further reductions in HbA1c, BW and SBP without additional safety concerns.

graphic
View largeDownload slide
Disclosure

M. Capehorn: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., McDonalds, Novo Nordisk, Consultant; Self; Lighterlife, Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Speaker’s Bureau; Self; Novo Nordisk. A. Catarig: Employee; Self; Novo Nordisk. O. Frenkel: Employee; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Thermo Fisher Scientific. C. Hindsberger: Consultant; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. M. Marre: Board Member; Self; Merck Sharp & Dohme Corp., Consultant; Self; Novo Nordisk. H. Price: Other Relationship; Self; Napp Pharmaceuticals, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Napp Pharmaceuticals, Novo Nordisk. R. E. Pratley: Other Relationship; Self; Hanmi Pharmaceutical, Merck Sharp & Dohme Corp., Metavention, Monster Energy Company, Inc., Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd.

Funding

Novo Nordisk A/S

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.